For many people with a genuine clinical need — a BMI of 30+, or 27+ with a weight-related health condition — Wegovy's value case is strong: trial data shows average weight loss of up to 20.7% at the highest licensed dose, alongside a specific UK licence for reducing cardiovascular risk in people with established cardiovascular disease, based on a major trial showing a 20% reduction in serious cardiac events. That cardiovascular indication is a genuine point of difference — it's a benefit shown to occur independently of how much weight was lost. Whether Wegovy is "worth it" for you specifically depends on your starting point, whether you have (or are at risk of) cardiovascular disease, your other options including NHS access, and whether you can commit to it consistently for the months it takes to see meaningful results.
You're paying for a licensed, MHRA-regulated pharmaceutical product manufactured to strict quality standards, a proper clinical consultation and ongoing prescriber oversight, and — when accessed through a GPhC-registered pharmacy — a supply chain that protects you from the counterfeit products increasingly circulating in this space. Wegovy is also one of the more established GLP-1 medicines in the UK, meaning there's a longer real-world safety track record behind it than more recently launched alternatives.
It's also worth separating the medicine's cost from the broader lifestyle changes it's licensed alongside. Wegovy is designed to work in combination with a reduced-calorie diet and increased physical activity, not as a replacement for them — the cost buys you a tool that makes those changes more achievable and sustainable, not a substitute for making any changes at all.
The Results You Can Expect For That InvestmentIn Wegovy's pivotal trials, participants lost an average of around 14.9% of their body weight at the standard 2.4mg dose, with more recent data on the higher 7.2mg dose showing averages up to 20.7%. Beyond the number on the scale, trial data also showed meaningful improvements in blood pressure, cholesterol and blood sugar control.
The Cardiovascular Case: A Genuine Point of DifferenceThis is where Wegovy's value proposition goes beyond weight loss alone. Wegovy holds a specific UK licence for reducing cardiovascular risk in adults with overweight or obesity and established cardiovascular disease (a prior heart attack, stroke, TIA, or peripheral arterial disease), based on the SELECT trial — one of the largest cardiovascular outcomes studies in this field, enrolling over 17,000 participants. Semaglutide reduced major adverse cardiovascular events by 20% compared with placebo, and follow-up analysis found this benefit occurred independently of how much weight participants actually lost, suggesting a cardioprotective effect beyond weight loss alone.
Why this matters for value
If you have existing cardiovascular disease, or a strong family history of it, this licensed indication represents a genuinely different kind of value than weight loss alone — you're potentially paying for a reduction in serious cardiac events, not just a smaller waist size. This is a meaningful point of difference from medicines that don't currently hold this same indication.
The NHS Route
Wegovy is available on the NHS through specialist Tier 3 weight management services, and since April 2026 through a more direct pathway for patients with established cardiovascular disease and a BMI of 27 or above. Waiting times for the Tier 3 route can extend well beyond a year in some areas — see our dedicated guide to NHS eligibility for weight loss injections for the full breakdown. For many people, private treatment is the only immediately available option.
Diet and Exercise Alone
Diet and exercise cost far less directly, but sustained weight loss through lifestyle changes alone is difficult to maintain for many people, particularly at the scale Wegovy's trial data shows. The relevant comparison is the realistic likelihood of achieving and sustaining a given result either way, factoring in your own history with previous attempts.
Weight Loss Surgery
Bariatric surgery produces substantial weight loss, but it's a major surgical procedure carrying its own risks and recovery time, typically at a private cost significantly higher than a year or more of Wegovy, unless accessed through the NHS with its own strict eligibility criteria and waiting times.
Hidden Costs and Savings to Consider- Reduced spending on food, given significantly decreased appetite, can partially offset the cost of treatment for some people
- Potential reductions in other medication costs if blood pressure, cholesterol or blood sugar improve enough to reduce or stop other prescriptions — though this should only ever be done under medical guidance
- For people with cardiovascular risk factors, the value of reduced long-term cardiac event risk is genuinely difficult to put a price on, but it's a real factor worth weighing
- Counterfeit or unregulated "cheaper" alternatives carry a real risk of being ineffective, incorrectly dosed, or dangerous — see our guide on how to spot fake weight loss injections for more detail
- If you haven't yet tried a sustained period of dietary and lifestyle changes, since Wegovy is licensed to work alongside these, not replace the need for them entirely
- If you're not in a position to commit to treatment for at least several months, since titration alone takes weeks, and meaningful results build over months
- If you meet strict NHS eligibility criteria and are able to wait for that route, which removes the direct cost
- If your BMI and health profile don't meet the standard licensing criteria (BMI 30+, or 27+ with a weight-related condition)
Important
Cost pressure should never lead you to a provider that skips a proper consultation, dispenses without a genuine prescription, or offers prices that seem implausibly low compared with the regulated market — these are the clearest signs of an unregulated or counterfeit source.
Ultimately, Wegovy's value isn't a fixed number — it depends heavily on your starting BMI and health conditions, whether you have or are at risk of cardiovascular disease, whether you have access to the NHS route, and whether you're genuinely ready to commit to it consistently for the months needed to see results. It's also worth being realistic about tolerance: if a course of treatment is abandoned early because of unmanaged side effects, that's money spent without reaching the point where meaningful weight loss typically occurs. That's exactly why this decision is best made during a proper consultation, rather than from a generic guide alone.
Wegovy vs Mounjaro: A Value Comparison Worth KnowingIt's worth being aware that Mounjaro has shown somewhat greater average weight loss than Wegovy in trial data (up to 22.5% vs 20.7% at their respective highest doses). If maximum weight loss is your only priority, that's relevant to your value calculation. But Wegovy's cardiovascular indication is a genuine point of difference Mounjaro doesn't currently hold — so the "better value" answer genuinely depends on which outcome matters more to you, not just which produces a bigger number on the scale.
Find Out If Wegovy Is Right For You
A free online consultation with our GPhC-registered pharmacy team can help you understand whether Wegovy represents good value for your specific health goals and circumstances.
Start Your Free Online Consultation → Use code SWITCH10 if you're switching from another providerHappy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- Wegovy® (semaglutide) UK Summary of Product Characteristics.
- NICE. Cardiovascular risk reduction prescribing pathway for semaglutide, April 2026.